Core Viewpoint - Benda Pharmaceutical's stock has shown a mixed performance in recent months, with a year-to-date increase of 24.99% but a decline of 10.42% over the past 20 days, indicating volatility in its market position [1][2]. Financial Performance - For the first half of 2025, Benda Pharmaceutical reported a revenue of 1.731 billion yuan, reflecting a year-on-year growth of 15.37%. However, the net profit attributable to shareholders decreased by 37.53% to 140 million yuan [2]. - The company has distributed a total of 669 million yuan in dividends since its A-share listing, with 184 million yuan distributed over the past three years [3]. Shareholder and Market Activity - As of June 30, 2025, the number of shareholders increased by 9.97% to 32,100, while the average number of circulating shares per person decreased by 9.08% to 13,064 shares [2]. - The stock's trading activity on September 30, 2023, showed a net inflow of 6.5472 million yuan from major funds, with significant buying and selling activity [1]. Company Overview - Benda Pharmaceutical, established on January 7, 2003, and listed on November 7, 2016, is primarily engaged in the research, production, and sales of pharmaceuticals, with 99.10% of its revenue coming from drug sales [1]. - The company operates within the pharmaceutical and biotechnology sector, focusing on cancer treatment drugs and innovative medicines [1].

Group 1: 科创债ETF市场 - The second batch of 14 Sci-tech bond ETFs was listed on September 24, with 5 products exceeding 10 billion yuan on the first day. The total market size surpassed 230 billion yuan by September 26, indicating rapid expansion in this segment of bond ETFs [1] - The rise of Sci-tech bonds and ETFs is supported by policy direction favoring technological innovation, marking a "tech moment" for the bond market [1] Group 2: 新股发行情况 - As of September 29, 76 new stocks have been issued in the A-share market this year, raising a total of 75 billion yuan, surpassing the total for the entire year of 2024 [1] - The majority of new listings are concentrated in sectors such as power equipment, automotive, electronics, and machinery, with power equipment leading at 16 new stocks [1] Group 3: 银行股调研 - Over 300 institutional surveys have been conducted on listed banks, with a focus on interest margins, asset quality, and credit issuance [2] - Regional banks in economically developed areas show strong performance resilience, and the banking sector is expected to benefit from increased inflows of insurance capital [2] Group 4: 绿色甲醇需求 - The demand for green methanol in the shipping industry is projected to increase over 100 times in the next five years, from tens of thousands of tons annually to 30-40 million tons by 2030 [2] - This growth is anticipated to create a new market worth over 100 billion yuan by 2030, with several A-share companies already positioning themselves in the green methanol sector [2] Group 5: AI眼镜市场 - The AI glasses industry is experiencing explosive growth, with major tech companies launching new products and increasing sales volumes [2] - Analysts suggest that the sector is transitioning from technological exploration to large-scale commercial use, with significant investment opportunities identified in the supply chain and optical display segments [2]

Core Viewpoint - Beida Pharmaceutical has submitted an application for the issuance of overseas listed shares (H-shares) and listing on the main board of the Hong Kong Stock Exchange as of September 29, 2025 [1] Financial Performance - For the first half of 2025, Beida Pharmaceutical reported revenue of 1.731 billion yuan and a net profit attributable to shareholders of 140 million yuan [1]

Group 1 - The core viewpoint of the article is that BeiGene has submitted a listing application to the Hong Kong Stock Exchange, with Morgan Stanley and CITIC Securities as joint sponsors [1] - The company has successfully transformed into a "platform-based pharmaceutical enterprise," integrating commercialization capabilities, drug research and development, business development layout, and an innovative ecosystem [1] - BeiGene is a pioneer and leader in China's innovative drug research and development industry, focusing on new drugs for cancer treatment, particularly leading in lung cancer therapy [1] Group 2 - The company has established a drug pipeline covering key lung cancer targets such as EGFR and ALK through independent research and strategic partnerships, and has expanded into breast cancer, kidney cancer, hematology, and ophthalmology [1] - To date, the company has successfully launched eight commercialized products, including five innovative drugs, one biosimilar, and two co-marketing products [1]

格隆汇9月30日丨贝达药业(300558.SZ)公布，公司已于2025 年9 月29 日向香港联合交易所有限公司(以 下简称"香港联交所")递交了发行境外上市股份(H股)并在香港联交所主板挂牌上市的申请，并于同日在 香港联交所网站刊登了本次发行并上市的申请资料。该申请资料为公司按照香港证券及期货事务监察委 员会(以下简称"香港证监会")及香港联交所的要求编制和刊发，为草拟版本，其所载资料可能会适时作 出更新及修订。 ...

证券代码：300558 证券简称：贝达药业 公告编号：2025-067 英文：https://www1.hkexnews.hk/app/sehk/2025/107742/documents/sehk2509290 3421.pdf 需要特别予以说明的是，本公告仅为境内投资者及时了解本次发行并上市的 相关信息而作出。本公告以及公司刊登于香港联交所网站的申请资料不构成也不 得被视作对任何个人或实体收购、购买或认购公司本次发行的境外上市股份（H 股）的要约或要约邀请。 公司本次发行并上市尚需取得中国证券监督管理委员会、香港证监会、香港 联交所等相关政府机关、监管机构、证券交易所的批准、核准或备案，并需综合 1 考虑市场情况以及其他因素方可实施，尚存在不确定性。公司将根据该事项的进 展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 贝达药业股份有限公司 关于向香港联交所递交境外上市股份（H 股）发行并上市申请 并刊发申请资料的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝达药业股份有限公司（以下简称"公司"）已于 2025 年 9 月 29 日向香港 ...

Group 1 - The core point of the article is that Beida Pharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange [2] - The joint sponsors for the listing are Morgan Stanley and CITIC Securities [2]

Core Viewpoint - Beida Pharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, marking its third attempt to go public in Hong Kong after two unsuccessful attempts in 2021 [1][4]. Group 1: Company Overview - Beida Pharmaceutical is a pioneer in China's innovative drug research and development industry, successfully transforming from a biotech company focused on innovative drug discovery to a leading and profitable biopharmaceutical company [4]. - The company has established an integrated platform driven by four core pillars: mature commercialization capabilities, comprehensive drug discovery and development capabilities, forward-looking business development layout, and a competitive innovation ecosystem [4]. Group 2: Product Pipeline and Market Position - Beida Pharmaceutical has launched eight commercialized products, including five innovative drugs and one biosimilar, achieving several "firsts" in China [5]. - The company has built a comprehensive drug pipeline targeting key lung cancer pathways, including EGFR and ALK, and is expanding into high-potential treatment areas such as breast cancer, kidney cancer, hematology, and ophthalmology [4][5]. Group 3: Financial Performance - For the fiscal years ending December 31, 2022, 2023, 2024, and the six months ending June 30, 2025, Beida Pharmaceutical reported revenues of approximately RMB 2.377 billion, RMB 2.456 billion, RMB 2.892 billion, and RMB 1.731 billion respectively [5][7]. - The annual profits for the same periods were approximately RMB 125 million, RMB 334 million, RMB 387 million, and RMB 131 million respectively [5][7].

据港交所9月29日披露，贝达药业股份有限公司(简称：贝达药业(300558.SZ))向港交所主板提交上市申请书，联席保荐人为摩根士丹利、中信证 券。值得注意的是，这已是贝达药业第三次启动港股上市计划。回溯2021年，公司曾于2月、12月两度向香港联合交易所递交招股书，但两次上 市尝试均未成功。 招股书显示，贝达药业是中国创新药研发行业的先行者与引领者，从专注创新药发现与研发的生物科技公司成功转型为行业领先、盈利良好的 生物制药公司。公司已打造自主研发、市场拓展、战略合作与生态圈建设"四驾马车"协同驱动的一体化平台，公司至今已成功推出八款商业化 产品，其中多项产品实现"中国首个"突破。自2011年首款产品上市当年起，公司连续多年实现盈利，稳居中国创新药企前列。 自2003年成立以来，公司始终致力于研发用于治疗肿瘤的新型药物，以应对肺癌及其他主要癌症领域中亟待解决的临床需求。一方面，通过自 主研发与战略合作相结合的模式，公司构建了涵盖关键肺癌靶点（包括表皮生长因子受体（EGFR）和间变性淋巴瘤激酶（ALK））的全面药 物管线，这有助于公司在创新靶向肺癌治疗领域确立领先地位。另一方面，公司不断拓展至高潜力治疗领域， ...

Core Viewpoint - Beida Pharmaceutical has submitted its third listing application to the Hong Kong Stock Exchange, with Morgan Stanley and CITIC Securities as joint sponsors, following two unsuccessful attempts in 2021 [1][4]. Company Overview - Beida Pharmaceutical is a pioneer in China's innovative drug research and development industry, successfully transforming from a biotech company focused on innovative drug discovery to a leading and profitable biopharmaceutical company [4][5]. - The company has established an integrated platform driven by four core pillars: independent research and development, market expansion, strategic cooperation, and ecosystem construction [4]. Product Pipeline - Beida has launched eight commercialized products, including five innovative drugs and one biosimilar, with a comprehensive pipeline covering key lung cancer targets and expanding into other high-potential treatment areas such as breast cancer, kidney cancer, hematology, and ophthalmology [5][4]. Financial Performance - The company reported revenues of approximately RMB 2.377 billion, RMB 2.456 billion, RMB 2.892 billion, and RMB 1.731 billion for the fiscal years 2022, 2023, 2024, and the first half of 2025, respectively [5][7]. - Net profits for the same periods were approximately RMB 125 million, RMB 334 million, RMB 387 million, and RMB 131 million [5][7].